# Transcriptomic response of skeletal muscle to acute aerobic versus combined exercise in chronic kidney disease

**Authors:** Luke A. Baker, Matthew Graham-Brown, Thomas J. Wilkinson, Alice C. Smith, Emma L. Watson

PMC · DOI: 10.1371/journal.pone.0324303 · PLOS One · 2026-02-25

## TL;DR

This study explores how skeletal muscle in people with chronic kidney disease responds to different types of exercise at the genetic level.

## Contribution

The study is the first to compare transcriptomic responses to aerobic and combined exercise in CKD skeletal muscle.

## Key findings

- Aerobic exercise triggered strong inflammatory gene expression in CKD skeletal muscle.
- Combined exercise upregulated genes related to stress response and downregulated mitochondrial pathways.
- Mitochondrial dysfunction may hinder exercise adaptation in CKD patients.

## Abstract

Chronic kidney disease (CKD) affects approximately 14% of the UK population and is associated with significant exercise intolerance, partly due to skeletal muscle dysfunction. While exercise is a potential therapeutic strategy, the molecular response of skeletal muscle to exercise in CKD remains poorly understood. This study aimed to characterise transcriptomic changes in skeletal muscle 24 hours after aerobic (AE) or combined aerobic and resistance exercise (CE) in non-dialysis CKD.

This study utilised muscle biopsies from participants in the ExTRA CKD trial with stage 3b–4 CKD stages 3b-4 (AE: 24 (15–32) ml/min/1.73m2; CE: 25 (19–31) ml/min/1.73m2). Participants (n = 4 per group) were randomised to 12 weeks of thrice-weekly AE or CE. Vastus lateralis skeletal muscle biopsies were collected at baseline and 24h after the first bout of exercise. RNA was extracted for Bulk RNA sequencing. Bulk RNA sequencing was performed, and differentially expressed genes (DEGs) were identified between baseline and post-exercise samples, followed by pathway enrichment analysis.

Following AE, 1480 genes were upregulated and 1554 downregulated. CE resulted in 556 upregulated and 115 downregulated genes. The most upregulated gene after AE was CHI3L1 (log₂FC 10.7), followed by SAA2 and PTX3, all associated with inflammation. After CE, SFN (log₂FC 6.8) and MT1A were among the most highly upregulated. Enrichment analysis showed strong activation of inflammatory and cellular senescence pathways, and downregulation of mitochondrial function-related processes, particularly after AE.

Both AE and CE triggered robust inflammatory gene expression responses in CKD skeletal muscle, which may be indicative of early repair processes. Unexpectedly, mitochondrial-related pathways were downregulated at 24h post exercise. In the absence of earlier post exercise timepoints, it is not possible to determine whether these findings reflect impaired mitochondrial adaptation, or instead represent a recovery phase return of mitochondrial gene expression levels to baseline. These results highlight mitochondrial dysfunction may be a potential barrier to effective exercise adaptation and a possible therapeutic target in this population.

## Linked entities

- **Genes:** CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116], SAA2 (serum amyloid A2) [NCBI Gene 6289], PTX3 (pentraxin 3) [NCBI Gene 5806], SFN (stratifin) [NCBI Gene 2810], MT1A (metallothionein 1A) [NCBI Gene 4489]
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** FLRT3 (fibronectin leucine rich transmembrane protein 3) [NCBI Gene 23767] {aka HH21}, IL17RE (interleukin 17 receptor E) [NCBI Gene 132014], MRAS (muscle RAS oncogene homolog) [NCBI Gene 22808] {aka M-RAs, NS11, R-RAS3, RRAS3}, CALM2 (calmodulin 2) [NCBI Gene 805] {aka CALM, CALML2, CAM1, CAM3, CAMC, CAMII}, Igf1 (insulin-like growth factor 1) [NCBI Gene 16000] {aka C730016P09Rik, Igf-1, Igf-I}, LYPD4 (LY6/PLAUR domain containing 4) [NCBI Gene 147719] {aka SMR}, ATP2B2 (ATPase plasma membrane Ca2+ transporting 2) [NCBI Gene 491] {aka DFNA82, PMCA2, PMCA2a, PMCA2i}, CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116] {aka ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, GADD45A (growth arrest and DNA damage inducible alpha) [NCBI Gene 1647] {aka DDIT1, GADD45}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, MYOD1 (myogenic differentiation 1) [NCBI Gene 4654] {aka CMYO17, CMYP17, MYF3, MYOD, MYODRIF, PUM}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, AKT2 (AKT serine/threonine kinase 2) [NCBI Gene 208] {aka HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA}, GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) [NCBI Gene 2903] {aka EPND, FESD, GluN2A, LKS, NMDAR2A, NR2A}, MYOG (myogenin) [NCBI Gene 4656] {aka MYF4, bHLHc3, myf-4}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, ZFP36L2 (ZFP36 like 2 zinc finger CCCH-type) [NCBI Gene 678] {aka BRF2, ERF-2, ERF2, OOMD13, OZEMA13, RNF162C}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, CCNA1 (cyclin A1) [NCBI Gene 8900] {aka CT146}, THBS1 (thrombospondin 1) [NCBI Gene 7057] {aka THBS, THBS-1, TSP, TSP-1, TSP1}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}, C3orf52 (chromosome 3 open reading frame 52) [NCBI Gene 79669] {aka HYPT15, TTMP}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3) [NCBI Gene 8503] {aka p55, p55-GAMMA, p55PIK}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, GADD45B (growth arrest and DNA damage inducible beta) [NCBI Gene 4616] {aka GADD45BETA, MYD118}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, Osmr (oncostatin M receptor) [NCBI Gene 18414] {aka OSMRB}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, Jak1 (Janus kinase 1) [NCBI Gene 16451] {aka BAP004, C130039L05Rik}, PERM1 (PPARGC1 and ESRR induced regulator, muscle 1) [NCBI Gene 84808] {aka C1orf170}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, SLC25A6 (solute carrier family 25 member 6) [NCBI Gene 293] {aka AAC3, ANT, ANT 2, ANT 3, ANT3, ANT3Y}, SAA2 (serum amyloid A2) [NCBI Gene 6289] {aka SAA}, CMKLR2 (chemerin chemokine-like receptor 2) [NCBI Gene 2825] {aka GPR1}, UNC13C (unc-13 homolog C) [NCBI Gene 440279], TGM2 (transglutaminase 2) [NCBI Gene 7052] {aka G(h), TG(C), TGC, hTG2, tTG}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, MCU (mitochondrial calcium uniporter) [NCBI Gene 90550] {aka C10orf42, CCDC109A, HsMCU}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, JAK3 (Janus kinase 3) [NCBI Gene 3718] {aka JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK}, Trim63 (tripartite motif-containing 63) [NCBI Gene 433766] {aka MuRF1, RF1, Rnf28}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, NDUFA9 (NADH:ubiquinone oxidoreductase subunit A9) [NCBI Gene 4704] {aka CC6, CI-39k, CI39k, COQ11, MC1DN26, NDUFS2L}, CXCL3 (C-X-C motif chemokine ligand 3) [NCBI Gene 2921] {aka CINC-2b, GRO3, GROg, MIP-2b, MIP2B, SCYB3}, CCL8 (C-C motif chemokine ligand 8) [NCBI Gene 6355] {aka HC14, MCP-2, MCP2, SCYA10, SCYA8}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}, TRAF3IP2 (TRAF3 interacting protein 2) [NCBI Gene 10758] {aka ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CANDF8}
- **Diseases:** hypertension (MESH:D006973), arthritis (MESH:D001168), insulin resistance (MESH:D007333), hypertrophy (MESH:D006984), myocardial infarction (MESH:D009203), ischaemic heart disease (MESH:D006331), muscle dysfunction (MESH:D009135), adiposity (MESH:D018205), type II diabetes (MESH:D003924), tissue injury (MESH:D017695), CE (MESH:D000092202), muscle regeneration (MESH:D019042), Mitochondrial dysfunction (MESH:D028361), physical (MESH:D059445), fibrosis (MESH:D005355), sarcopenia (MESH:D055948), inflammation (MESH:D007249), muscle atrophy (MESH:D009133), CKD (MESH:D051436), atrophy (MESH:D001284), Diabetic (MESH:D003920), valvular heart disease (MESH:D006349), muscle weakness (MESH:D018908), AE (MESH:C538054), overweight (MESH:D050177), atrophy of type II fibres (MESH:D014897), 3b (MESH:C537391), obese (MESH:D009765)
- **Chemicals:** CE (-), phosphocreatine (MESH:D010725), heme (MESH:D006418), ATP (MESH:D000255), NAD+ (MESH:D009243), nitrogen (MESH:D009584), TRIzol (MESH:C411644), CE (MESH:D002563), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** A1C
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935244/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935244/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935244/full.md

---
Source: https://tomesphere.com/paper/PMC12935244